Invicta Diagnostic Releases Standalone and Consolidated Financial Results for March 31, 2026
Invicta Diagnostic Limited reported its audited financial results for the half year and financial year ended March 31, 2026. The company announced the approval of its Standalone and Consolidated Financial Statements, alongside detailed reports on its cash flow and utilization of funds raised through the Initial Public Offer (IPO).The financial results provide a comprehensive view of the group’s performance, encompassing data from multiple subsidiaries and associate entities.
Financial Statement Highlights
The company provided audited financial results for both Standalone and Consolidated entities. The financial statements are presented in Lakhs (₹).Consolidated Balance Sheet (As at March 31, 2026)
The consolidated balance sheet showed total assets of 6,024.87 Lakhs as at March 31, 2026, compared to 1,359.84 Lakhs at March 31, 2025.| Particulars | As at March 31, 2026 | As at March 31, 2025 |
|---|---|---|
| Share Capital | 1,257.20 | N/A |
| Reserves and Surplus | 3,735.06 | 3,117.0 |
| TOTAL Shareholders Funds | 4,992.26 | 1,359.84 |
| TOTAL Liabilities | 2,121.64 | 2121.64 |
| TOTAL Assets | 6,024.87 | N/A |
Standalone Balance Sheet (As at March 31, 2026)
The standalone financial structure saw a total of 5,296.89 Lakhs in assets.| Particulars | As at March 31, 2026 | As at March 31, 2025 |
|---|---|---|
| Share Capital | 841.79 | 1,278.20 |
| Reserves and Surplus | 436.41 | 1,278.20 |
| TOTAL Shareholders Funds | 1,278.20 | 1,278.20 |
| TOTAL Assets | 5,296.89 | 1,746.04 |
Revenue and Profitability
The combined total income for the group reached 2,140.91 Lakhs for the year ended March 31, 2026.| Financial Metric | H1 Ended March 31, 2026 | Preceding H1 Ended September 30, 2025 | Corresponding H1 March 31, 2025 | Current Year (Mar 31, 2026) | Previous Year (Mar 31, 2025) |
|---|---|---|---|---|---|
| Total Income | 990.64 | 1,150.27 | 0.00 | 2,140.91 | 1,773.42 |
The consolidated total net profit before tax for the year ended March 31, 2026, was 700.85 Lakhs.
Cash Flow Analysis
The company provided detailed cash flow statements for both consolidated and standalone activities.Consolidated Cash Flow Statement
Net Cash Flow from Operating Activities (A) stood at 293.21 Lakhs, rising from 655.86 Lakhs in the previous year. This was significantly influenced by a reduction in cash generated from operations, despite a major capital infusion of 2,983.64 Lakhs during the financing period.| Activity | March 31, 2026 (Lakhs) | March 31, 2025 (Lakhs) |
|---|---|---|
| Net Cash From Operating Activities (A) | 293.21 | 655.86 |
| Net Cash From Investing Activities (B) | (1,367.13) | (522.97) |
| Net Cash From Financing Activities (C) | 3,079.10 | N/A |
| NET INCREASE IN CASH & CASH EQUIVALENTS (A)+(B)+(C) | 2,005.17 | 82.57 |
Standalone Cash Flow Statement
Operationally, the Standalone net cash from operating activities was 319.84 Lakhs for the year ended March 31, 2026. The primary source of funding came from financing activities, totaling 2,979.39 Lakhs.Utilization of IPO Proceeds
Invicta Diagnostic Limited reported that as of March 31, 2026, there was no deviation or variation in the utilization of funds raised through the Initial Public Offer (IPO).The company had raised a total of 2,812.48 Lakhs through Public Issues/Rights Issues/Preferential Issues/QIP/Others on December 4, 2025.
The funds utilized across the period were:
- Funding capital expenditure for purchase of medical equipment: 227.79 Lakhs
- General Corporate purposes: 238 Lakhs
- Issue related Expenses: 278.59 Lakhs
- Total Utilized Amount: 744.38 Lakhs
The total unutilized amount stood at 2,068.1 Lakhs, with the unutilized amount from the capital expenditure object lying in Fixed deposit and Current account with banks.
INVICTA Stock Price Movement
As of 1:34 PM, shares of Invicta Diagnostic Limited are holding steady at ₹89.5 in live trading, showing no immediate movement for the day. The stock remains within a trading range of ₹85.05 to ₹93.95, supported by a total volume of 19,200 shares traded.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.